CD4 and melanoma: In the case of immune checkpoint blockade therapy, it was recently shown that an increase in a subset of central “memory-like” (CD27+Fas−CD45RA−CCR7+) CD4+ T cells in patients with malignant melanoma could be used as a predictor of clinical response to PD-1 blockade therapy (190, 191).